BRAF V600E-Mutant Colorectal Cancer: Triplet and Doublet Therapies Improve Quality of Life

An updated analysis of a phase 3 trial reports that encorafenib/cetuximab, alone or in combination with binimetinib, improves quality of life compared with the current standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer whose disease progressed after one or two prior therapies.The BEACON CRC study, the results of which were published in the New England Journal of Medicine in October, investigated the efficacies of encorafenib/cetuximab/binimetinib (triplet therapy) a...
Continue reading

Pembrolizumab for Non-Muscle Invasive Bladder Cancer With Ashish Kamat, MD, MBBS

The FDA recently approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) therapy. The approval was based on Keynote 057 (NCT02625961), a phase 2 trial in which pembrolizumab produced a complete response rate of 41% in patients with this disease. In this interview with i3 Health, Ashish Kamat, MD, MBBS, Professor of Urologic Oncology (Surgery) and Cancer Research at MD Anderson...
Continue reading

Fedratinib for Improved Quality of Life in Myelofibrosis With Ruben Mesa, MD

Patients with myelofibrosis can experience debilitating symptoms that negatively impact their quality of life. In the phase 3 JAKARTA trial, a team of researchers led by Ruben Mesa, MD, the Director of MD Anderson Cancer Center at the University of Texas, San Antonio, found that fedratinib, an oral JAK2 inhibitor, decreased symptom severity and markedly improved quality of life in patients with intermediate- or high-risk primary or secondary myelofibrosis. Dr. Mesa presented the results of the t...
Continue reading

Veliparib Adds Benefits to Ovarian Carcinoma Treatment: An Interview With Robert L. Coleman, MD

High-grade serous ovarian carcinoma is the most malignant form of ovarian cancer, with a high recurrence rate and a low survival rate. While patients are commonly treated with induction chemotherapy consisting of paclitaxel plus carboplatin, there is a need to develop additional first- and second-line therapies to increase survival in patients with this disease.In their study now published in The New England Journal of Medicine, Robert L. Coleman, MD, a Professor in the Department of Gynecologic...
Continue reading

Triplet Therapy for BRAF V600E-Mutated Metastatic Colorectal Cancer

In metastatic colorectal cancer, the BRAF V600E mutation, which affects around 10% of patients, portends a poor outcome. Initial standard chemotherapy often fails, and after it does, patients survive for a median of only 4 to 6 months. A phase 3 trial reports a significant improvement in overall survival with two different treatments: a triplet therapy consisting of encorafenib (BraftoviTM, Array BioPharma), binimetinib (MektoviTM, Array BioPharma), and cetuximab (Erbitux®, Eli Lilly); and ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.